Author: admin

“Interstitial Cystitis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Cystitis Market.

The Interstitial Cystitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Interstitial Cystitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Interstitial Cystitis treatment therapies with a considerable amount of success over the years.

• Interstitial Cystitis companies working in the treatment market are Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharmaceuticals, Inc., Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Vaneltix Pharma, Inc./Prevail Infoworks, Inc, and others, are developing therapies for the Interstitial Cystitis treatment

• Emerging Interstitial Cystitis therapies in the different phases of clinical trials are- Sunobinop, IMB 150, SI-722, IW-3300, Peppermint oil, Ferumoxytol, BOTOX, VNX001, and others are expected to have a significant impact on the Interstitial Cystitis market in the coming years.

• In April 2024, Glycologix, Inc. (“Glycologix”), a clinical-stage biopharma company specializing in biopolymer therapies for soft tissue protection and repair, announced that results from its multi-center Phase 1b trial of GLX-100 in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) will be presented at the 2025 American Urological Association (AUA) Annual Meeting.

• In June 2023, Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialized biopharmaceutical firm dedicated to meeting unmet medical requirements by reimagining existing medications, announced the enrollment of the first participant in a Phase 2 trial for AlenuraTM. This trial involves four arms and compares the product candidate to its individual components, heparin and lidocaine, as well as a placebo. AlenuraTM is an innovative bladder instillation product in its clinical stage, integrating lidocaine, a well-known anesthetic, in a novel alkalinized formulation with heparin, a glycoso-amino-glycan (GAG), found in bladder mucous membranes. AlenuraTM shows promise as a potential primary pharmaceutical treatment for acute pain among patients diagnosed with interstitial cystitis/bladder pain syndrome.

Interstitial Cystitis Overview

Interstitial Cystitis, also known as Bladder Pain Syndrome (BPS), is a chronic condition characterized by inflammation and irritation of the tissues lining the wall of the bladder. It is a type of painful bladder syndrome that can lead to discomfort, pressure, and pain in the pelvic region. The exact cause of interstitial cystitis is not well understood, and it can be challenging to diagnose.

Get a Free Sample PDF Report to know more about Interstitial Cystitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight

Emerging Interstitial Cystitis Drugs Under Different Phases of Clinical Development Include:

• Sunobinop: Imbrium Therapeutics

• IMB 150: PureTech Health

• SI-722: Seikagaku Corporation

• IW-3300: Ironwood Pharmaceuticals, Inc.

• Peppermint oil: Integrative Therapeutics, Inc.

• Ferumoxytol: Lipella Pharmaceuticals, Inc.

• BOTOX: Allergan

• VNX001: Vaneltix Pharma, Inc./Prevail Infoworks, Inc

Interstitial Cystitis Route of Administration

Interstitial Cystitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Interstitial Cystitis Molecule Type

Interstitial Cystitis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Interstitial Cystitis Pipeline Therapeutics Assessment

• Interstitial Cystitis Assessment by Product Type

• Interstitial Cystitis By Stage and Product Type

• Interstitial Cystitis Assessment by Route of Administration

• Interstitial Cystitis By Stage and Route of Administration

• Interstitial Cystitis Assessment by Molecule Type

• Interstitial Cystitis by Stage and Molecule Type

DelveInsight’s Interstitial Cystitis Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Interstitial Cystitis product details are provided in the report. Download the Interstitial Cystitis pipeline report to learn more about the emerging Interstitial Cystitis therapies

Some of the key companies in the Interstitial Cystitis Therapeutics Market include:

Key companies developing therapies for Interstitial Cystitis are – Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Ironwood Pharmaceuticals, Inc., Vaneltix Pharma, Inc., Prevail Infoworks, Inc., and others.

Interstitial Cystitis Pipeline Analysis:

The Interstitial Cystitis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Cystitis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Cystitis Treatment.

• Interstitial Cystitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Interstitial Cystitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Cystitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Interstitial Cystitis drugs and therapies

Interstitial Cystitis Pipeline Market Drivers

• Increase in prevalence of Interstitial Cystitis, increase in Research and Development are some of the important factors that are fueling the Interstitial Cystitis Market.

Interstitial Cystitis Pipeline Market Barriers

• However, lack of approved drugs, lack of understanding about the cause of the disease and other factors are creating obstacles in the Interstitial Cystitis Market growth.

Scope of Interstitial Cystitis Pipeline Drug Insight

• Coverage: Global

• Key Interstitial Cystitis Companies: Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharmaceuticals, Inc., Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Vaneltix Pharma, Inc./Prevail Infoworks, Inc, and others

• Key Interstitial Cystitis Therapies: Sunobinop, IMB 150, SI-722, IW-3300, Peppermint oil, Ferumoxytol, BOTOX, VNX001, and others

• Interstitial Cystitis Therapeutic Assessment: Interstitial Cystitis current marketed and Interstitial Cystitis emerging therapies

• Interstitial Cystitis Market Dynamics: Interstitial Cystitis market drivers and Interstitial Cystitis market barriers

Request for Sample PDF Report for Interstitial Cystitis Pipeline Assessment and clinical trials

Table of Contents

1. Interstitial Cystitis Report Introduction

2. Interstitial Cystitis Executive Summary

3. Interstitial Cystitis Overview

4. Interstitial Cystitis- Analytical Perspective In-depth Commercial Assessment

5. Interstitial Cystitis Pipeline Therapeutics

6. Interstitial Cystitis Late Stage Products (Phase II/III)

7. Interstitial Cystitis Mid Stage Products (Phase II)

8. Interstitial Cystitis Early Stage Products (Phase I)

9. Interstitial Cystitis Preclinical Stage Products

10. Interstitial Cystitis Therapeutics Assessment

11. Interstitial Cystitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Interstitial Cystitis Key Companies

14. Interstitial Cystitis Key Products

15. Interstitial Cystitis Unmet Needs

16 . Interstitial Cystitis Market Drivers and Barriers

17. Interstitial Cystitis Future Perspectives and Conclusion

18. Interstitial Cystitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Cystitis Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Lipella Pharma, Allergan, PureTech Health, Imbrium Therapeutics, Ironwood

The Diabetic Foot Ulcers market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Foot Ulcers pipeline products will significantly revolutionize the Diabetic Foot Ulcers market dynamics.

DelveInsight’s “Diabetic Foot Ulcers Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Foot Ulcers, historical and forecasted epidemiology as well as the Diabetic Foot Ulcers market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Diabetic Foot Ulcers market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Foot Ulcers Market Forecast

Some of the key facts of the Diabetic Foot Ulcers Market Report:

• The Diabetic Foot Ulcers market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In July 2025, Eluciderm Inc. has obtained FDA clearance for its Investigational New Drug (IND) application to initiate a Phase I/IIa open-label trial. The study will assess the safety and effectiveness of ELU-42, a topical spray-on solution designed to promote healing in patients with diabetic foot ulcers (DFUs).

• In March 2025, Orthofix Medical Inc. received both FDA 510(k) clearance and the European CE Mark for its TrueLok™ Elevate Transverse Bone Transport (TBT) System. The TrueLok Elevate is designed to support limb preservation by addressing bony and soft tissue deformities or defects, including nonhealing wounds and diabetic foot ulcers.

• In February 2025, PolarityBio revealed that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to its regenerative tissue product, SkinTE, for the treatment of Wagner Grade 1 Diabetic Foot Ulcers (DFU).

• In January 2025, BioStem Technologies, Inc. (OTC: BSEM), a prominent MedTech firm specializing in placental-derived products for advanced wound care, has launched the BR-AM-DFU (BioREtain® Amniotic Membrane – Diabetic Foot Ulcers) clinical trial. The study aims to assess the effectiveness of Vendaje® compared to the current standard of care in treating patients with non-healing diabetic foot ulcers.

• In January 2025, ION, a clinical-stage regenerative medicine company specializing in exosome-based therapeutics, announced the completion of patient enrollment in its Phase 2 clinical trial for Purified Exosome Product™ (PEP™) to treat Diabetic Foot Ulcers (DFUs). This milestone represents a significant advancement in the company’s efforts to develop innovative therapies for chronic wound care.

• In October 2024, A clinical study conducted by Kerecis, the designer of fish-skin grafts, shows that these grafts are more effective than the standard treatments for closing various types of diabetic foot ulcers. The study’s results, published in the New England Journal of Medicine, reveal that fish-skin grafts from the Finland-based company resulted in significantly higher healing rates, sustained effectiveness, and faster healing.

• In 2023, the United States recorded the highest number of total prevalent cases of diabetic foot ulcers (DFU) among the 7 major markets (7MM).

• In 2023, male patients accounted for 60% of diabetic foot ulcer (DFU) cases in the 7MM, while females made up 40%.

• In 2023, among diagnosed diabetic foot ulcer (DFU) cases in the United States, 35% were acute or healed wounds, while 65% were chronic or unhealed wounds.

• Key Diabetic Foot Ulcers Companies: Amniox (TissueTech), Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others

• Key Diabetic Foot Ulcers Therapies: TTAX01 (Neox Cord 1K), TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others, and others

• The Diabetic Foot Ulcers epidemiology based on age-specific cases analyzed that the US accounts for the highest number of cases in the age group 45–64 years followed by ≥75 years.

• The Diabetic Foot Ulcers market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Foot Ulcers pipeline products will significantly revolutionize the Diabetic Foot Ulcers market dynamics.

Diabetic Foot Ulcers Overview

Diabetic Foot Ulcers (DFUs) are open sores or wounds that commonly occur on the feet of people with diabetes. They develop due to a combination of factors such as poor blood circulation, nerve damage (neuropathy), and high blood sugar levels, which impair healing. If left untreated, DFUs can lead to serious infections and, in severe cases, amputation. Early detection, proper foot care, and medical management are essential to prevent complications.

Get a Free sample for the Diabetic Foot Ulcers Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market

Diabetic Foot Ulcers Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diabetic Foot Ulcers Epidemiology Segmentation:

The Diabetic Foot Ulcers market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Diabetic Foot Ulcers

• Prevalent Cases of Diabetic Foot Ulcers by severity

• Gender-specific Prevalence of Diabetic Foot Ulcers

• Diagnosed Cases of Episodic and Chronic Diabetic Foot Ulcers

Download the report to understand which factors are driving Diabetic Foot Ulcers epidemiology trends @ Diabetic Foot Ulcers Epidemiology Forecast

Diabetic Foot Ulcers Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Foot Ulcers market or expected to get launched during the study period. The analysis covers Diabetic Foot Ulcers market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Foot Ulcers Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Foot Ulcers Therapies and Key Companies

• TTAX01 (Neox Cord 1K): Amniox (TissueTech)

• ENGENSIS (VM202): Helixmith

• ON101 (fespixon): Oneness Biotech

• ENERGI-F703: Energenesis Biomedical

• TOP-N53: Topadur Pharma

• CYP-006TK: Cynata Therapeutics

• TWB-103: Transwell Biotech

• APO-2: Aposcience

• ILP100: Ilya Pharma

• MBN-101: Microbion Corporation

• EscharEx: MediWound

• Adipose-derived regenerative cells: Paracrine, INC.

• Galnobax: NovaLead Pharma

Discover more about therapies set to grab major Diabetic Foot Ulcers market share @ Diabetic Foot Ulcers Treatment Landscape

Diabetic Foot Ulcers Market Drivers

• Rise in global prevalence of foot ulcers in diabetic patients

• Increasing research and development activities in the development of biologics

• Technological advancements

Diabetic Foot Ulcers Market Barriers

• High cost of the advanced wound care therapies

• Adverse effects associated with the drugs

Scope of the Diabetic Foot Ulcers Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Diabetic Foot Ulcers Companies: Amniox (TissueTech), Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others

• Key Diabetic Foot Ulcers Therapies: TTAX01 (Neox Cord 1K), TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others, and others

• Diabetic Foot Ulcers Therapeutic Assessment: Diabetic Foot Ulcers current marketed and Diabetic Foot Ulcers emerging therapies

• Diabetic Foot Ulcers Market Dynamics: Diabetic Foot Ulcers market drivers and Diabetic Foot Ulcers market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Diabetic Foot Ulcers Unmet Needs, KOL’s views, Analyst’s views, Diabetic Foot Ulcers Market Access and Reimbursement

To know more about Diabetic Foot Ulcers companies working in the treatment market, visit @ Diabetic Foot Ulcers Clinical Trials and Therapeutic Assessment

Table of Contents

1. Diabetic Foot Ulcers Market Report Introduction

2. Executive Summary for Diabetic Foot Ulcers

3. SWOT analysis of Diabetic Foot Ulcers

4. Diabetic Foot Ulcers Patient Share (%) Overview at a Glance

5. Diabetic Foot Ulcers Market Overview at a Glance

6. Diabetic Foot Ulcers Disease Background and Overview

7. Diabetic Foot Ulcers Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Foot Ulcers

9. Diabetic Foot Ulcers Current Treatment and Medical Practices

10. Diabetic Foot Ulcers Unmet Needs

11. Diabetic Foot Ulcers Emerging Therapies

12. Diabetic Foot Ulcers Market Outlook

13. Country-Wise Diabetic Foot Ulcers Market Analysis (2020–2034)

14. Diabetic Foot Ulcers Market Access and Reimbursement of Therapies

15. Diabetic Foot Ulcers Market Drivers

16. Diabetic Foot Ulcers Market Barriers

17. Diabetic Foot Ulcers Appendix

18. Diabetic Foot Ulcers Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Foot Ulcers Market to Experience Notable Growth by 2034, DelveInsight Predicts | Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corp

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Chronic Obstructive Pulmonary Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Obstructive Pulmonary Disease Market.

Some of the key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Obstructive Pulmonary Disease treatment therapies with a considerable amount of success over the years.

• Chronic Obstructive Pulmonary Disease companies working in the treatment market are AstraZeneca, Sanofi, Amgen, Synairgen, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Chiesi Farmaceutici S.p.A, Novartis, Genentech, Palobiofarma, Pulamtrix, and others, are developing therapies for the Chronic Obstructive Pulmonary Disease treatment

• Emerging Chronic Obstructive Pulmonary Disease therapies in the different phases of clinical trials are- Benralizumab, Dupilumab, Tezepelumab, SNG001, GSK3923868, Ensifentrine, SAR440340, CHF 6001, QBW-251, Tezepelumab, Anti-ST2, PBF-680, PUR1800, and others are expected to have a significant impact on the Chronic Obstructive Pulmonary Disease market in the coming years.

• In July 2025, Upstream Bio has initiated dosing in its randomized Phase II VENTURE trial evaluating verekitug, an antibody antagonist of the thymic stromal lymphopoietin (TSLP) receptor, in patients with chronic obstructive pulmonary disease (COPD). This double-blind, placebo-controlled study will assess the safety and efficacy of the therapy in approximately 670 adults with moderate-to-severe COPD. Participants will receive either 100 mg of verekitug every 12 weeks, 400 mg every 24 weeks, or placebo, with treatment durations spanning 60 to 108 weeks.

• In April 2025, Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company dedicated to advancing treatments for asthma and chronic obstructive pulmonary disease (COPD), has received encouraging feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), specifically the Division of Pulmonology, Allergy, and Critical Care within the Office of Immunology and Inflammation.

• In March 2025, SMSbiotech achieved a major milestone in advancing its regenerative medicine platform, receiving approval to initiate a Phase I clinical trial in Australia (registration number: ANZCTR12624001140549p). The trial aims to assess the safety and tolerability of the company’s novel Small Mobile stem (SMS) cell therapy for treating Chronic Obstructive Pulmonary Disease (COPD).

• In January 2025, Aer Therapeutics (“Aer”), a biopharmaceutical company focused on developing innovative inhaled therapies for mucus-related lung diseases, announced that the first patient has been dosed in its Phase 2a proof-of-concept (POC) clinical trial of fexlamose (previously known as AER-01) for Chronic Obstructive Pulmonary Disease (COPD).

• In September 2024, GSK’s asthma drug Nucala (mepolizumab) achieved its primary endpoint in a Phase III trial for treating patients with chronic obstructive pulmonary disease (COPD). Results from the MATINEE study revealed that adding Nucala to inhaled maintenance therapy significantly lowered the annualized rate of moderate or severe exacerbations compared to placebo.

• In January 2024, Theravance Biopharma, Inc. (NASDAQ: TBPH) has released findings from the Phase 4 PIFR-2 trial of YUPELRI® (revefenacin) inhalation solution, the sole once-daily, nebulized long-acting muscarinic antagonist (LAMA) authorized in the U.S. for COPD maintenance therapy. The PIFR-2 study aimed to illustrate superior lung function enhancement with YUPELRI administered via standard jet nebulizer versus Spiriva® (tiotropium) delivered through a dry powder inhaler (Spiriva® HandiHaler®) in severe to very severe COPD patients with suboptimal peak inspiratory flow rate (PIFR).

• In April 2024, Amgen (NASDAQ: AMGN) shared an update on the Phase 2a COURSE trial results for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which will be presented at the American Thoracic Society (ATS) 2024 International Conference. The trial, which investigated tezepelumab in patients with moderate to very severe COPD across various eosinophil levels and inflammatory drivers, showed promising results. The study did not exclude patients based on baseline eosinophil count (BEC) and enrolled a diverse group. Tezepelumab reduced the annualized rate of moderate or severe COPD exacerbations by 17% compared to placebo, though the result did not reach statistical significance.

Chronic Obstructive Pulmonary Disease Overview

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that causes breathing difficulties due to airflow obstruction. It encompasses conditions such as chronic bronchitis and emphysema, primarily resulting from long-term exposure to irritants like cigarette smoke, air pollution, and occupational dust. Symptoms include persistent cough, mucus production, wheezing, and shortness of breath, especially during physical activity. COPD is characterized by its chronic nature, often leading to worsening lung function over time. While there is no cure, management options include medications, pulmonary rehabilitation, and lifestyle changes, such as smoking cessation, to improve quality of life and reduce symptoms.

Get a Free Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

Emerging Chronic Obstructive Pulmonary Disease Drugs Under Different Phases of Clinical Development Include:

• Benralizumab: AstraZeneca

• Dupilumab: Sanofi

• Tezepelumab: Amgen

• SNG001: Synairgen

• GSK3923868: GlaxoSmithKline

• Ensifentrine: Verona Pharma

• SAR440340: Regeneron Pharma

• CHF 6001: Chiesi Farmaceutici S.p.A

• QBW-251: Novartis

• Tezepelumab: AstraZeneca

• Anti-ST2: Genentech

• PBF-680: Palobiofarma

• PUR1800: Pulamtrix

Chronic Obstructive Pulmonary Disease Route of Administration

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous

• Intramuscular

Chronic Obstructive Pulmonary Disease Molecule Type

Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment

• Chronic Obstructive Pulmonary Disease Assessment by Product Type

• Chronic Obstructive Pulmonary Disease By Stage and Product Type

• Chronic Obstructive Pulmonary Disease Assessment by Route of Administration

• Chronic Obstructive Pulmonary Disease By Stage and Route of Administration

• Chronic Obstructive Pulmonary Disease Assessment by Molecule Type

• Chronic Obstructive Pulmonary Disease by Stage and Molecule Type

DelveInsight’s Chronic Obstructive Pulmonary Disease Report covers around 70+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Obstructive Pulmonary Disease product details are provided in the report. Download the Chronic Obstructive Pulmonary Disease pipeline report to learn more about the emerging Chronic Obstructive Pulmonary Disease therapies

Some of the key companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include:

Key companies developing therapies for Chronic Obstructive Pulmonary Disease are – Afimmune, Allakos, Amgen/AstraZeneca, Arrowhead Pharmaceuticals, Astellas Pharma, AstraZeneca, Boehringer-Ingelheim, Brickell Biotech, Chiesi Farmaceutici S.p.A., Chiesi USA, Inc., Dimerix, EpiEndo Pharmaceuticals, Genentech, GlaxoSmithkline, GSNOR Therapeutics, InMed Pharmaceuticals, Ionis Pharmaceuticals, KeyMed Biosciences, Laboratoires SMB, Mereo BioPharma, Meridigen Biotech, Nephron Pharmaceuticals, Novartis, Pulmatrix Inc., Pulmotect, Quercegen Pharmaceuticals, Regend Therapeutics, Regeneron Pharmaceuticals/Sanofi, Sulfateq BV, Synairgen, Tetherex Pharmaceuticals, Verona Pharma, Vertex Pharmaceuticals, and several others.

Chronic Obstructive Pulmonary Disease Pipeline Analysis:

The Chronic Obstructive Pulmonary Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.

• Chronic Obstructive Pulmonary Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease drugs and therapies

Chronic Obstructive Pulmonary Disease Pipeline Market Drivers

• Rising disease burden associated with COPD, increasing focus on therapy development, favorable insurance coverage for COPD treatment are some of the important factors that are fueling the Chronic Obstructive Pulmonary Disease Market.

Chronic Obstructive Pulmonary Disease Pipeline Market Barriers

• However, concerns regarding the long term use of current ICS/LABA inhalers, poor regimen adherence by patients, treatment costs and other factors are creating obstacles in the Chronic Obstructive Pulmonary Disease Market growth.

Scope of Chronic Obstructive Pulmonary Disease Pipeline Drug Insight

• Coverage: Global

• Key Chronic Obstructive Pulmonary Disease Companies: AstraZeneca, Sanofi, Amgen, Synairgen, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Chiesi Farmaceutici S.p.A, Novartis, Genentech, Palobiofarma, Pulamtrix, and others

• Key Chronic Obstructive Pulmonary Disease Therapies: Benralizumab, Dupilumab, Tezepelumab, SNG001, GSK3923868, Ensifentrine, SAR440340, CHF 6001, QBW-251, Tezepelumab, Anti-ST2, PBF-680, PUR1800, and others

• Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies

• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers

Request for Sample PDF Report for Chronic Obstructive Pulmonary Disease Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Obstructive Pulmonary Disease Report Introduction

2. Chronic Obstructive Pulmonary Disease Executive Summary

3. Chronic Obstructive Pulmonary Disease Overview

4. Chronic Obstructive Pulmonary Disease- Analytical Perspective In-depth Commercial Assessment

5. Chronic Obstructive Pulmonary Disease Pipeline Therapeutics

6. Chronic Obstructive Pulmonary Disease Late Stage Products (Phase II/III)

7. Chronic Obstructive Pulmonary Disease Mid Stage Products (Phase II)

8. Chronic Obstructive Pulmonary Disease Early Stage Products (Phase I)

9. Chronic Obstructive Pulmonary Disease Preclinical Stage Products

10. Chronic Obstructive Pulmonary Disease Therapeutics Assessment

11. Chronic Obstructive Pulmonary Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Obstructive Pulmonary Disease Key Companies

14. Chronic Obstructive Pulmonary Disease Key Products

15. Chronic Obstructive Pulmonary Disease Unmet Needs

16 . Chronic Obstructive Pulmonary Disease Market Drivers and Barriers

17. Chronic Obstructive Pulmonary Disease Future Perspectives and Conclusion

18. Chronic Obstructive Pulmonary Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: COPD Clinical Trials Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, Synairgen, AstraZeneca, Sanofi, Organicell Regenerative Medicine

DelveInsight’s “Single Ventricle Heart Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Single Ventricle Heart Disease, historical and forecasted epidemiology as well as the Single Ventricle Heart Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Single Ventricle Heart Disease, offering comprehensive insights into the Single Ventricle Heart Disease revenue trends, prevalence, and treatment landscape. The report delves into key Single Ventricle Heart Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Single Ventricle Heart Disease therapies. Additionally, we cover the landscape of Single Ventricle Heart Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Single Ventricle Heart Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Single Ventricle Heart Disease space.

To Know in detail about the Single Ventricle Heart Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Single Ventricle Heart Disease Market Forecast

Some of the key facts of the Single Ventricle Heart Disease Market Report:

• The Single Ventricle Heart Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In July 2025, Mezzion Pharmaceuticals, Inc., the U.S. arm of Mezzion Pharma Co., Ltd. (KOSDAQ: 140410), is a late-stage biopharmaceutical company dedicated to advancing treatments for rare and underserved conditions. Based in New Jersey, the company is spearheading the global clinical development and commercialization of JURVIGO® (udenafil), an investigational therapy in Phase 3 trials for individuals with single ventricle heart disease and Fontan physiology. JURVIGO® has been granted Rare Pediatric Disease Designation by the U.S. FDA, and Mezzion plans to submit a New Drug Application (NDA) upon completion of the FUEL-2 trial.

• In September 2024, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a biopharmaceutical company specializing in muscle diseases, has announced top-line results for EDG-7500 from its Phase 1 trial in healthy participants and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). EDG-7500 is an innovative oral, selective cardiac sarcomere modulator developed to reduce early contraction velocity and improve impaired cardiac relaxation linked to HCM.

• Key Single Ventricle Heart Disease Companies: Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion, Metcela, and others

• Key Single Ventricle Heart Disease Therapies: Udenafil, AZD1305, Bosentan, Captopril, BAY1142524, QVA149, Ivabradine, REGN5381, Macitentan, JRM-001, and others

• The Single Ventricle Heart Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Single Ventricle Heart Disease pipeline products will significantly revolutionize the Single Ventricle Heart Disease market dynamics.

• The analysis of single ventricle heart disease revealed that these defects are uncommon, affecting approximately five in every 100,000 newborns. They are also among the most complex heart conditions, typically necessitating at least one surgical intervention.

• The analysis found that the most prevalent congenital heart defects (ACHDs) include atrial septal defect (20.5%), ventricular septal defect (20.5%), tetralogy of Fallot (12.9%), and univentricular heart (UVH)/single ventricle (SV) (6.6%).

• It was discovered that hypoplastic left heart syndrome, the most prevalent type of univentricular heart disease, occurs in 2 to 3 out of every 10,000 births, with a higher incidence in males.

• The analysis revealed that double outlet right ventricle occurs in 0.009 cases per 10,000 live births, while double inlet left ventricle is seen in up to 0.01 cases per 10,000 live births.

• The analysis found that tricuspid atresia occurs in approximately 1 in every 10,000 live births, while Ebstein anomaly is seen in about 0.5 per 10,000 live births, with a noted gender preference.

Single Ventricle Heart Disease Overview

Single Ventricle Heart Disease is a rare congenital heart defect where one of the heart’s ventricles is underdeveloped or missing. This condition disrupts the normal flow of blood, as the heart cannot effectively pump oxygenated blood to the body and deoxygenated blood to the lungs.

Get a Free sample for the Single Ventricle Heart Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/single-ventricle-heart-disease-market

Single Ventricle Heart Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Single Ventricle Heart Disease Epidemiology Segmentation:

The Single Ventricle Heart Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Single Ventricle Heart Disease

• Prevalent Cases of Single Ventricle Heart Disease by severity

• Gender-specific Prevalence of Single Ventricle Heart Disease

• Diagnosed Cases of Episodic and Chronic Single Ventricle Heart Disease

Download the report to understand which factors are driving Single Ventricle Heart Disease epidemiology trends @ Single Ventricle Heart Disease Epidemiology Forecast

Single Ventricle Heart Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Single Ventricle Heart Disease market or expected to get launched during the study period. The analysis covers Single Ventricle Heart Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Single Ventricle Heart Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Single Ventricle Heart Disease Therapies and Key Companies

• Udenafil: Mezzion Pharma Co

• AZD1305: AstraZeneca

• Bosentan: Rigshospitalet

• Captopril: Astrazeneca

• BAY1142524: Bayer

• QVA149: Novartis

• Ivabradine: Amgen

• REGN5381: Regeneron Pharma

• Macitentan: Actelion

• JRM-001: Metcela

Discover more about therapies set to grab major Single Ventricle Heart Disease market share @ Single Ventricle Heart Disease Treatment Landscape

Single Ventricle Heart Disease Market Drivers

• Increasing Awareness and Early Diagnosis

• Advancements in Surgical Techniques

• Growing Focus on Pediatric Cardiology

• Development of Novel Therapies

• Supportive Government Initiatives

• Improved Post-Surgical Care

• Increasing Healthcare Accessibility

Single Ventricle Heart Disease Market Barriers

• High Treatment Costs

• Limited Awareness in Low-income Regions

• Complexity of Treatment

• Long-term Health Risks

• Challenges in Personalized Medicine

• Risk of Heart Transplantation

• Limited Market Size

Scope of the Single Ventricle Heart Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Single Ventricle Heart Disease Companies: Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion, Metcela, and others

• Key Single Ventricle Heart Disease Therapies: Udenafil, AZD1305, Bosentan, Captopril, BAY1142524, QVA149, Ivabradine, REGN5381, Macitentan, JRM-001, and others

• Single Ventricle Heart Disease Therapeutic Assessment: Single Ventricle Heart Disease current marketed and Single Ventricle Heart Disease emerging therapies

• Single Ventricle Heart Disease Market Dynamics: Single Ventricle Heart Disease market drivers and Single Ventricle Heart Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Single Ventricle Heart Disease Unmet Needs, KOL’s views, Analyst’s views, Single Ventricle Heart Disease Market Access and Reimbursement

To know more about Single Ventricle Heart Disease companies working in the treatment market, visit @ Single Ventricle Heart Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Single Ventricle Heart Disease Market Report Introduction

2. Executive Summary for Single Ventricle Heart Disease

3. SWOT analysis of Single Ventricle Heart Disease

4. Single Ventricle Heart Disease Patient Share (%) Overview at a Glance

5. Single Ventricle Heart Disease Market Overview at a Glance

6. Single Ventricle Heart Disease Disease Background and Overview

7. Single Ventricle Heart Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Single Ventricle Heart Disease

9. Single Ventricle Heart Disease Current Treatment and Medical Practices

10. Single Ventricle Heart Disease Unmet Needs

11. Single Ventricle Heart Disease Emerging Therapies

12. Single Ventricle Heart Disease Market Outlook

13. Country-Wise Single Ventricle Heart Disease Market Analysis (2020–2034)

14. Single Ventricle Heart Disease Market Access and Reimbursement of Therapies

15. Single Ventricle Heart Disease Market Drivers

16. Single Ventricle Heart Disease Market Barriers

17. Single Ventricle Heart Disease Appendix

18. Single Ventricle Heart Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Single Ventricle Heart Disease Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma

“Parkinson’s Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.

The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Parkinson’s Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Parkinson’s Disease treatment therapies with a considerable amount of success over the years.

• Parkinson’s Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson’s Disease treatment

• Emerging Parkinson’s Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson’s Disease market in the coming years.

• In June 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced its decision to advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson’s disease. This move is based on findings from the Phase IIb PADOVA study and ongoing open-label extension (OLE) studies from both PADOVA and the earlier Phase II PASADENA trial.

• In February 2025, AstraZeneca’s diabetes drug Bydureon (exenatide) did not slow the progression of motor symptoms in Parkinson’s disease during a Phase III trial. Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression. However, results published in The Lancet revealed that the trial did not achieve its primary or secondary endpoints.

• In January 2025, BlueRock Therapeutics, a U.S.-based subsidiary of Bayer, has advanced bemdaneprocel, its investigational cell therapy for Parkinson’s disease, to Phase III trials following a Phase I study that demonstrated the treatment was well tolerated.

• In January 2025, BIAL has announced the completion of the full dose regimen for the first participant in the multicenter Phase II ACTIVATE trial of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase) for treating Parkinson’s disease (PD). This therapy is specifically being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene mutation (GBA-PD). Designed for once-daily oral administration, BIA 28-6156 aims to restore sphingolipid recycling to address the underlying cause of PD.

• In December 2024, Belgian pharmaceutical company UCB decided to discontinue the development of minzasolmin for Parkinson’s disease after the ORCHESTRA study did not achieve its primary or secondary endpoints. In the ORCHESTRA proof-of-concept trial (NCT04658186), minzasolmin—an investigational oral small-molecule inhibitor targeting alpha-synuclein misfolding—failed to show superiority over placebo.

• In December 2024, Novotech, a leading global full-service clinical Contract Research Organization (CRO), released its latest report titled Parkinson’s Disease: Global Clinical Trial Landscape 2024. The report provides valuable insights into current trends, key opportunities, and prevailing challenges in Parkinson’s disease (PD) research, serving as an important resource for organizations developing therapies for this intricate neurodegenerative disorder.

Parkinson’s Disease Overview

Parkinson’s disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson’s disease experience difficulties with movement control.

Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights

Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:

• KM-819: FAScinate Therapeutics

• Prasinezumab: Hoffmann-La Roche

• P2B001: Pharma Two B Ltd.

• NPT1220-478: Neuropore Therapies, Inc.

• Dapansutrile: Olatec Therapeutics

• UCB7853: UCB Biopharma

• UB-312: Vaxxinity

• Emrusolmin: Modag

• PT320: Peptron

• KDT-3594: Kissei Pharmaceutical

• Tavapadon: Cerevel Therapeutics

Parkinson’s Disease Route of Administration

Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Parkinson’s Disease Molecule Type

Parkinson’s Disease Products have been categorized under various Molecule types, such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Parkinson’s Disease Pipeline Therapeutics Assessment

• Parkinson’s Disease Assessment by Product Type

• Parkinson’s Disease By Stage and Product Type

• Parkinson’s Disease Assessment by Route of Administration

• Parkinson’s Disease By Stage and Route of Administration

• Parkinson’s Disease Assessment by Molecule Type

• Parkinson’s Disease by Stage and Molecule Type

DelveInsight’s Parkinson’s Disease Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies

Some of the key companies in the Parkinson’s Disease Therapeutics Market include:

Key companies developing therapies for Parkinson’s Disease are – Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others.

Parkinson’s Disease Pipeline Analysis:

The Parkinson’s Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.

• Parkinson’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies

Parkinson’s Disease Pipeline Market Drivers

• Increasing prevalence of Parkinson’s Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson’s Disease Market.

Parkinson’s Disease Pipeline Market Barriers

• However, lack of awareness and delayed diagnosis, side effects associated with Parkinson’s disease treatment drugs and other factors are creating obstacles in the Parkinson’s Disease Market growth.

Scope of Parkinson’s Disease Pipeline Drug Insight

• Coverage: Global

• Key Parkinson’s Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

• Key Parkinson’s Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies

• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers

Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials

Table of Contents

1. Parkinson’s Disease Report Introduction

2. Parkinson’s Disease Executive Summary

3. Parkinson’s Disease Overview

4. Parkinson’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Parkinson’s Disease Pipeline Therapeutics

6. Parkinson’s Disease Late Stage Products (Phase II/III)

7. Parkinson’s Disease Mid Stage Products (Phase II)

8. Parkinson’s Disease Early Stage Products (Phase I)

9. Parkinson’s Disease Preclinical Stage Products

10. Parkinson’s Disease Therapeutics Assessment

11. Parkinson’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Parkinson’s Disease Key Companies

14. Parkinson’s Disease Key Products

15. Parkinson’s Disease Unmet Needs

16 . Parkinson’s Disease Market Drivers and Barriers

17. Parkinson’s Disease Future Perspectives and Conclusion

18. Parkinson’s Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson’s Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail